{
 "name": "鼎晉生技",
 "slug": "tw-7876",
 "aliases": [
  "鼎晉生技股份有限公司",
  "OBIGEN PHARMA",
  "7876"
 ],
 "ticker": "7876",
 "industry": "生技醫療業",
 "website": "https://www.obigenpharma.com/",
 "summary": "鼎晉生技（7876）是興櫃的生技醫療類股公司，2020 年成立，2025 年登錄興櫃。基本資料取自臺灣證券交易所／證券櫃檯買賣中心公開資料；重大訊息見 https://drugnews.com.tw/filings/ 。",
 "facts": [
  {
   "claim": "公司全名",
   "value": "鼎晉生技股份有限公司",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "英文簡稱",
   "value": "OBIGEN PHARMA",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "產業類別",
   "value": "生技醫療業",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "掛牌市場",
   "value": "證券櫃檯買賣中心興櫃",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "登錄興櫃日期",
   "value": "2025-11-24",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "成立日期",
   "value": "2020-12-10",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "董事長",
   "value": "蔣永芳",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "總經理",
   "value": "周珮芬",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "實收資本額",
   "value": 1072617500,
   "unit": "新台幣元",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "簽證會計師事務所",
   "value": "資誠聯合會計師事務所",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "公司網址",
   "value": "https://www.obigenpharma.com/",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "管線：OBI-858（760 kDa A型肉毒桿菌素；台灣）",
   "value": "中重度皺眉紋｜兩項樞紐第3期試驗執行中｜台灣",
   "unit": "",
   "as_of": "2026-09-07",
   "source": "https://www.obigenpharma.com/announcements/0907-announcement-123-obi858",
   "note": "OBI-858-004/005；公司公告原文明列三期執行中；二期劑量選擇 OBI-858-002 與重複劑量安全性 OBI-858-003 均已結束。公司網站列表上架日 2026-09-09，本文公告日期及事實發生日為 2026-09-07，採原公告日期。"
  },
  {
   "claim": "催化劑：OBI-858",
   "value": "第3期人體臨床試驗預計完成｜2026（公司預估）｜已公告",
   "unit": "",
   "as_of": "2026-09-07",
   "source": "https://www.obigenpharma.com/announcements/0907-announcement-123-obi858",
   "note": "公司重大公告第 6 點：預計 2026 年完成，實際時程依執行進度調整；不推估確切日期。"
  },
  {
   "claim": "管線：OBI-858（A型肉毒桿菌素；美國）",
   "value": "中重度皺眉紋｜美國 FDA 核准展開第2期臨床試驗｜美國",
   "unit": "",
   "as_of": "2026-02-09",
   "source": "https://www.obigenpharma.com/announcements/announcements-17",
   "note": "公司官網重大公告列表發布日期 2026-02-09；美國時間 2026-02-06 獲准。核准對象為人體臨床試驗，非產品上市許可。"
  },
  {
   "claim": "催化劑：OBI-858",
   "value": "台灣生物製劑許可申請（BLA）目標送件｜2027年初（公司預估）｜已公告",
   "unit": "",
   "as_of": "2025-08-26",
   "source": "https://www.obigenpharma.com/announcements/announcements-13",
   "note": "公司原公告訂目標為 2026 年底完成試驗、2027 年初提交 BLA；後續 2026-09-07 公告仍列 2026 年完成三期，未公布新的 BLA 日期，保留原始預估並明示來源日期。"
  }
 ],
 "responses": [],
 "provided_by": "public_sources",
 "verified_by": "Drugnews｜藥時事",
 "verified_at": "2026-10-22",
 "disclosure": "Drugnews 依公開來源（公司公告、公開資訊觀測站、試驗登錄、主管機關文件）整理，於 verified_at 逐條核對來源；未經公司審閱。",
 "url": "https://drugnews.com.tw/companies/tw-7876.json",
 "generated_at": "2026-10-23T11:48:56.615Z"
}